Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Cytek Biosciences Q4 2025 Earnings Call - Return to growth led by recurring revenue and APAC momentum, but profitability pressured by a large tax valuation allowance and higher operating costs
Cytek closed 2025 with accelerating top-line momentum, reporting Q4 revenue of $62.1 million, up 8% year-over-year, and full-year revenue of $201.5 million, up 1%. Growth was broad-based by region in ...
- Q4 revenue $62.1M, +8% year-over-year; full-year 2025 revenue $201.5M, +1% year-over-year.
- Installed base reached 3,664 units after adding 208 instruments in Q4; 2025 unit order volume rose 22% year-over-year and accelerated to 26% in Q4.
- Recurring revenue now 34% of total and grew 21% year-over-year, driven by service, reagents, and cloud adoption.
- +12 more takeaways
Asure Software Q4 2025 Earnings Call - Asure Central and Luna AI set the stage for a 2026 revenue inflection
Asure closed 2025 with clear top-line momentum and cleaner margins, driven by the rollout of Asure Central and rapid adoption of its Luna AI agent. Full-year revenue reached $140.5 million, up 17% yea...
- Full-year 2025 revenue was $140.5 million, up 17% year over year; Q4 revenue was $39.3 million, up 28% year over year.
- Recurring revenue for 2025 was $127.3 million, an 11% increase year over year; Q4 recurring revenue was $33.7 million, up 18% year over year.
- Organic growth accelerated to 10% in Q4 from 4% in Q3, with full-year organic growth of 5% in 2025.
- +12 more takeaways
Pacira BioSciences Q4 2025 Earnings Call - EXPAREL momentum, IP runway to 2039 and data-rich pipeline set 2026 agenda
Pacira presents a clear reset. FY2025 revenue was $726 million, EXPAREL volumes showed a second-half acceleration and Q4 sales reached $155.8 million, while the company secured a material IP and comme...
- FY2025 revenue was $726 million, with Q4 EXPAREL sales of $155.8 million versus $147.7 million in Q4 2024, reflecting roughly 7% volume growth in the quarter.
- Pacira reported its highest-ever non-GAAP gross margins in Q4, 80% versus 79% a year ago, and guided 2026 non-GAAP gross margins to 77%–79% while targeting a 5 percentage point improvement versus 2024 by 2030 under its 5x30 plan.
- Management says the legal settlement with Fresenius provides EXPAREL volume-limited runway visibility through 2039, and the IP estate has expanded to 21 patents across two families, materially strengthening exclusivity compared with one patent a year ago.
- +12 more takeaways
BioLife Solutions Q4 2025 Earnings Call - BPM dominance fuels 29% FY growth, company guiding to first GAAP profit
BioLife closed 2025 with a clean, narrower portfolio and a clear commercial story. Total revenue from continuing operations rose 29% to $96.2 million, driven by biopreservation media, which made up ab...
- Full-year 2025 revenue from continuing operations was $96.2 million, up 29% year-over-year; Q4 revenue was $24.8 million, up 20% year-over-year.
- Biopreservation media (BPM) accounted for roughly 85% of Q4 revenue and remains the core cash engine for the business.
- Top 20 BPM customers represent about 80% of BPM revenue, concentrating visibility but also client risk.
- +17 more takeaways
Castle Biosciences Fourth Quarter and Full Year 2025 Earnings Call - TissueCypher Momentum and AdvanceAD Early Traction Set the Stage While Margin and Guideline Headwinds Persist
Castle closed 2025 with strong top-line momentum driven by TissueCypher’s 86% volume jump and steady DecisionDx-Melanoma growth, while launching AdvanceAD-Tx into limited access where early clinician ...
- Total revenue for 2025 was $344.2 million, with Q4 revenue of $87.0 million, exceeding guidance.
- TissueCypher test reports jumped 86% in 2025 to 39,014 reports; patient penetration exiting 2025 is roughly 11%, clinician penetration about 25-30% suggesting a large runway.
- DecisionDx-Melanoma delivered 39,083 test reports in 2025, up 9% year-over-year, with patient penetration near 31% and total ordering clinicians approaching 17,000 lifetime.
- +12 more takeaways
Puma Biotechnology Q4 2025 Earnings Call - Nerlynx sales inch up as inventory and China royalty boost results, alisertib trials accelerate
Puma posted a modest quarter where headline revenue gains mask a familiar pattern, inventory builds and a one-time royalty payout did a lot of the heavy lifting. NERLYNX net product revenue rose to $5...
- Total revenue for Q4 2025 was $75.5 million, with NERLYNX net product revenue of $59.9 million and royalty revenue of $15.6 million.
- Q4 NERLYNX product revenue rose versus Q3 2025 ($51.9 million) and Q4 2024 ($54.4 million), driven in part by a $5.7 million inventory build at specialty pharmacies and distributors.
- NERLYNX ex-factory bottle sales were 3,298 in Q4 2025, up roughly 12% quarter-over-quarter and 11% year-over-year; estimated inventory increased by about 343 bottles in Q4.
- +13 more takeaways
OrthoPediatrics Corp. Q4 2025 Earnings Call - Hit first quarterly free cash flow positive, guiding to 2026 FCF breakeven with double-digit growth
OrthoPediatrics closed 2025 with broad-based momentum: Q4 revenue rose 17% to $61.6 million, full-year revenue grew 15%, adjusted EBITDA improved sharply and the company reported its first-ever quarte...
- Q4 2025 revenue $61.6 million, up 17% year-over-year; full-year 2025 revenue up 15%.
- Q4 adjusted EBITDA was $4.8 million, a 59% improvement versus Q4 2024; management says full-year 2025 adjusted EBITDA rose nearly 75% year-over-year.
- Company generated $10 million of free cash flow in Q4, its first quarter of positive FCF in company history; full-year cash usage improved to $15 million from $41 million in 2024.
- +10 more takeaways
Korea Electric Power Corporation Q4 2025 Earnings Call - FY2025 profit lifted by lower fuel costs and higher nuclear output, but Q4 clouded by volatile provisions and subsidiary costs
KEPCO reported consolidated FY2025 operating income of KRW 13,524.8 billion and net income of KRW 8,737.2 billion, driven by a 4.3% rise in revenue and a sharp drop in fuel costs. Fuel and purchased-p...
- FY2025 consolidated operating income: KRW 13,524.8 billion (KRW 13.5248 trillion).
- FY2025 consolidated revenue: KRW 97,434.5 billion, up 4.3% year-over-year; power sales KRW 93,004.6 billion, up 4.6%.
- FY2025 consolidated net income: KRW 8,737.2 billion.
- +16 more takeaways
Banco Macro 4Q 2025 Earnings Call - Profit Rebound Masked by ARS 82.9bn Restructuring, Adjusted ROE Target ~8% for 2026
Banco Macro returned to profitability in 4Q25, but the headline masks a heavy reset. Reported net income was ARS 100 billion in the quarter after ARS 82.9 billion of restructuring and severance charge...
- Reported 4Q25 net income was ARS 100 billion, recovering from the prior quarter loss, but 26% below 4Q24.
- Excluding ARS 82.9 billion of restructuring and severance charges, 4Q25 net income would be ARS 183 billion; FY25 adjusted net income would be ARS 393.7 billion.
- Bank recorded ARS 82.9 billion of restructuring expenses in 4Q25, with about ARS 36 billion of related personnel exits impacting 2026, and management expects similar items to appear across early 2026.
- +13 more takeaways
Ducommun Incorporated Q4 2025 Earnings Call - Record Margins and Big Missile Orders Push Defense-Led Growth
Ducommun closed Q4 2025 with a new revenue record of $215.8 million, stronger margins and a missile-booking surge that underpins managements claim that VISION 2027 is on track. Gross margin hit 27.7% ...
- Q4 2025 revenue hit a record $215.8 million, up 9.4% year over year and the 19th consecutive quarter of year over year growth.
- Adjusted gross margin was 27.7% in Q4, up from 24.0% on an adjusted basis in Q4 2024; about 100 basis points of the quarter's margin benefit came from favorable product mix.
- Adjusted EBITDA reached a record 17.5% ($37.9 million) in Q4 2025, up $10.6 million versus Q4 2024; management still views a blended 2026 EBITDA baseline near 16.5% after removing mix effects.
- +13 more takeaways